119831-72-0 | Fmoc-Arg(Pmc)-OH

Packsize	Purity	Availability	Price	Discounted Price
1g	98%	in stock	$47.00	$33.00
5g	98%	in stock	$111.00	$78.00
25g	98%	in stock	$417.00	$292.00
100g	98%	in stock	$1,269.00	$889.00
250g	98%	in stock	$2,954.00	$2,068.00

Description

• Catalog Number: AA33164
• Chemical Name: Fmoc-Arg(Pmc)-OH
• CAS Number: 119831-72-0
• Molecular Formula: C35H42N4O7S
• Molecular Weight: 662.7956
• MDL Number: MFCD00065618
• SMILES: O=C(N[C@H](C(=O)O)CCCNC=NNS(=O)(=O)c1c(C)c(C)c2c(c1C)CCC(O2)(C)C)OCC1c2ccccc2-c2c1cccc2

Computed Properties

• Complexity: 1230
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 47
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 4
• Rotatable Bond Count: 12
• XLogP3: 5.5

Upstream Synthesis Route

Fmoc-Arg(Pmc)-OH is a key reagent used in peptide synthesis to introduce arginine residues into the peptide chain. Arginine is an important amino acid with a positively charged guanidinium side chain, making it essential for protein-protein interactions and enzymatic functions.In chemical synthesis, Fmoc-Arg(Pmc)-OH is particularly useful due to its ability to protect the arginine side chain. The Fmoc group on the α-amino group provides temporary protection during peptide assembly, preventing unwanted side reactions. The Pmc (2,2,5,7,8-pentamethylchroman-6-sulfonyl) group shields the guanidinium side chain, which is crucial for maintaining the specific properties of arginine within the peptide structure.This reagent allows chemists to precisely control the introduction of arginine residues at specific positions within a peptide sequence. By selectively deprotecting and coupling Fmoc-Arg(Pmc)-OH with other amino acids, complex peptides can be synthesized with high purity and efficiency. Its application in solid-phase peptide synthesis has contributed significantly to the development of novel peptide-based drugs, structural studies, and biochemical research.

Literature

• The discovery, characterization and crystallographically determined binding mode of an FMOC-containing inhibitor of HIV-1 protease.

  Bioorganic & medicinal chemistry 19970701